

Eir Ventures completes investment in ISD Immunotech, as company advances its leads candidate ISD017 for treatment of Systemic Lupus Erythematosus (SLE)

- *Eir Ventures have joined the Company's existing investor syndicate led by Novo Holdings and with participation of private investors as well as founders and management.*
- *Stephan Christgau, founding partner at Eir Ventures will join the company's board of directors.*

Copenhagen, October 11, 2021. ISD Immunotech ApS ("ISD"), a biotech company developing new anti-inflammatory treatments, today announced that Eir Ventures have completed an investment in the company. The financing will provide additional funding for development of the company's lead candidate ISD017, a novel first in class therapy for treatment of Systemic Lupus Erythematosus (SLE).

Ingelise Saunders, Executive Chairman of ISD commented *"We are delighted to welcome Eir Ventures to ISD and see the commitment from the Venture fund as a very important recognition of the company. The financing is an important step for us as it will secure that all planned preclinical studies can be completed as well as securing the company runway until 2023"*.

Stephan Christgau, Founding partner at Eir Ventures have joined the ISD Board of directors. Stephan Christgau holds a PhD in Protein Chemistry and Immunology from DTU and UCSF, he has broad executive experience from private as well as public biotech companies with responsibilities for R&D, operations, clinical development and corporate strategy. Stephan was a founding member of the corporate life science venture capital group Novo Seeds, before co-founding Eir Ventures. He states *"We have been very impressed with the scientific and clinical expertise behind ISD and see great potential in the company's lead program ISD017. The company has completed a number of pre-clinical studies demonstrating the potential of its therapy in animal models of SLE as well as potentially other inflammatory diseases. We are delighted to join the investor syndicate and look forward to work with ISD to bring its promising therapies into the clinic"*.

For more information please contact:

Eir Venture
Stephan Christgau
stephan.christgau@eirventures.eu
Mob: +45 30 67 47 90

ISD Immunotech
Ingelise Saunders
is@ is@isd-immunotech.com
Mob : +45 20203687

About ISD Immunotech

ISD Immunotech is a private preclinical biotech focusing on the development of a peptide therapeutic, ISD017, which uniquely blocks all aspects of STimulator of INterferon Genes (“STING”) pathway overactivation in severe SLE. The company, headquartered in Copenhagen, is a spinout of Aarhus University, Denmark, which is an academic center of excellence in STING biology. ISD Immunotech is run by a team of seasoned biotech and pharma executives with decades of peptide R&D experience. The company is supported by world class academic and clinical advisors with deep insight into STING biology, animal disease models and clinical lupus research. The company is funded by Novo Seeds. www.isd-immunotech.com

About Eir Ventures

Eir Ventures is a Life science focused venture fund, with a strong foundation in the Nordic Biotech ecosystem, that will invest in companies at early stage, as well as more mature opportunities. The fund started its investment activities in 2020 and seeks investment opportunities addressing significant unmet medical needs for new therapies, medical technology and digital health. Eir Ventures AB is led by a team of experienced life science investors, and backed by a strong investor syndicate including Saminvest, the European Investment Fund (EIF), Vækstfonden, Novo Holdings, private investors as well as Nordic universities. Eir Ventures is a registered alternative investment fund, under the Swedish Alternative Investment Funds Managers Act. <https://eirventures.eu/>